Alyssa A Toorop

11PUBLICATIONS
16CO-AUTHORS
Nanotoxicology, health and safetyNeurosciences not elsewhere classifiedEnvironmental epidemiologyGene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper

|Nov 04, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp

|Jan 18, 2024
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.

Alyssa A Toorop, Samantha Noteboom, Martijn D Steenwijk

|Nov 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen

|Jan 24, 2023
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.

Alyssa A Toorop, Laura Hogenboom, Karien Bloem

|Jan 13, 2023
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.

Alyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis

Pageof 2

Frequent Collaborators

7 joint publications

Eva Mm Strijbis

7 joint publications

Zoé LE van Kempen

4 joint publications

Theo Rispens

3 joint publications

Christiaan M Roosendaal